GSK vs NVO Comparison: AI Score, Valuation, Performance and Upside
Compare GSK and Novo Nordisk ADRs by vaccine revenue vs Ozempic and Wegovy monopoly, pipeline optionality, dividend track record, and which European pharma offers better defensive income with long-term growth potential.
Use this GSK vs Novo Nordisk comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
GSK holds the edge across 3 of 5 key metrics in this comparison. GSK has delivered stronger 1-year price return (+39.35% vs -27.71%), though NVO has the better forward P/E setup (2.28x vs 9.95x for GSK). Analyst consensus implies meaningfully more upside for GSK (+13.10%) than for NVO (-3.06%).
| Metric | GSK | NVO |
|---|---|---|
| AI score | 41.9 | 39.0 |
| AI rank | #958 | #1252 |
| Latest close | $51.35 | $48.77 |
| 1M return | +0.51% | +2.87% |
| 6M return | +7.37% | -18.76% |
| 1Y return | +39.35% | -27.71% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | GSK | NVO |
|---|---|---|
| 1Y ago | $14.47K (+44.7%) started 2025-07-24 | $7.57K (-24.3%) started 2025-07-24 |
| 5Y ago | $20.32K (+103.2%) started 2021-07-26 | $13.59K (+35.9%) started 2021-07-26 |
| 10Y ago | $33.54K (+235.4%) started 2016-07-25 | $28.67K (+186.7%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | GSK | NVO |
|---|---|---|
| Market cap | $102.84B | $215.7B |
| Trailing P/E | 13.51 | 11.67 |
| Forward P/E | 9.95 | 2.28 |
| Price/Sales | 2.34 | 0.66 |
| EV/Revenue | 3.58 | 1.04 |
| Analyst target | $58.08 | $47.28 |
| Target upside | +13.10% | -3.06% |
| Metric | GSK | NVO |
|---|---|---|
| Revenue growth | 1.50% | 24.00% |
| Earnings growth | 8.40% | 67.10% |
| EPS growth | +8.40% | +67.10% |
| FCF margin | +9.21% | -3.67% |
| Operating margin | N/A | N/A |
| Profit margin | 17.78% | 37.21% |
| ROIC proxy | 40.91% | 71.40% |
| Return on equity | 40.91% | 71.40% |
| Dividend yield | 3.54% | 3.74% |
| Beta | 0.30 | 0.36 |
| Debt/equity | 109.70 | 72.09 |
| Current ratio | 0.79 | 0.79 |
| Quick ratio | 0.51 | 0.54 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | GSK | NVO |
|---|---|---|---|
| 1Y | Growth | +39.35% | -27.71% |
| CAGR | +39.38% | -27.73% | |
| Sharpe ratio | 1.21 | -0.45 | |
| Max drawdown | 18.53% | 49.17% | |
| Max daily drop | 5.64% | 21.83% | |
| Max wkly drop | 7.81% | 33.45% | |
| 5Y | Growth | +61.71% | +21.64% |
| CAGR | +10.10% | +4.00% | |
| Sharpe ratio | 0.33 | 0.18 | |
| Max drawdown | 37.63% | 74.70% | |
| Max daily drop | 8.69% | 21.83% | |
| Max wkly drop | 13.87% | 33.45% | |
| 10Y | Growth | +85.82% | +122.08% |
| CAGR | +6.39% | +8.31% | |
| Sharpe ratio | 0.19 | 0.27 | |
| Max drawdown | 37.63% | 74.70% | |
| Max daily drop | 11.04% | 21.83% | |
| Max wkly drop | 17.31% | 33.45% |
| Category | GSK | NVO |
|---|---|---|
| Company | GSK | NVO |
| Sector | N/A | N/A |
| Industry | N/A | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.